XTL Biopharmaceuticals Ltd.
XTLB
$1.27
$0.043.25%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 2.01M | 2.21M | 2.38M | 2.88M | 3.72M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 29.00K | 77.00K | 118.00K | 66.00K | 71.00K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 11.00K | -- | -- | -- | 14.00K |
| Total Current Assets | 2.05M | 2.28M | 2.50M | 2.94M | 3.81M |
|
|
|||||
| Total Current Assets | 2.05M | 2.28M | 2.50M | 2.94M | 3.81M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 380.00K | 380.00K | 380.00K | 380.00K | 380.00K |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 2.43M | 2.66M | 2.88M | 3.32M | 4.19M |
|
|
|||||
| Total Accounts Payable | 1.00K | 162.00K | 163.00K | 241.00K | 2.00K |
| Total Accrued Expenses | 205.00K | -- | -- | -- | 185.00K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 206.00K | 162.00K | 163.00K | 241.00K | 187.00K |
|
|
|||||
| Total Current Liabilities | 206.00K | 162.00K | 163.00K | 241.00K | 187.00K |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 206.00K | 162.00K | 163.00K | 241.00K | 187.00K |
|
|
|||||
| Common Stock & APIC | 160.45M | 160.45M | 160.45M | 160.45M | 160.45M |
| Retained Earnings | -158.25M | -157.97M | -157.75M | -157.39M | -156.47M |
| Treasury Stock & Other | 20.00K | 20.00K | 20.00K | 20.00K | 20.00K |
| Total Common Equity | 2.22M | 2.50M | 2.72M | 3.08M | 4.00M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 2.22M | 2.50M | 2.72M | 3.08M | 4.00M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 2.22M | 2.50M | 2.72M | 3.08M | 4.00M |
|
|
|||||
